Faes Farma : Hikma terminates its licensing agreement for Bilastine in the US
>Faes unveils Bilastine’s approval in China… - The company announced, via a regulatory filing, that the Chinese regulator (NPMA) has approved Bilastine to treat urticaria in adults and children over 12 after successfully completing the local clinical trials. The approval unlocks a market opportunity for Faes of c. $ 0.5bn (third largest antihistamine market) that is projected to grow at a rate of 12% over the next decade. Menarini (already selling Bilastine in some co...Faes Farma is engaged in the health care research, manufacture and sale of prescription pharmaceuticals, over-the-counter pharmaceuticals and fine chemicals, URGO bandages and dressings and LAZLO cosmetics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.